Skip Navigation


ToxSci Advance Access originally published online on March 3, 2006
Toxicological Sciences 2006 91(2):586-599; doi:10.1093/toxsci/kfj148
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
91/2/586    most recent
kfj148v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (28)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Halpern, W. G.
Right arrow Articles by Baker, K. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Halpern, W. G.
Right arrow Articles by Baker, K. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic Effects

Wendy G. Halpern*,1,2, Patrick Lappin{dagger},3, Thomas Zanardi{dagger},3, Wendy Cai*,2, Marta Corcoran*,2, John Zhong*,2 and Kevin P. Baker*,2

* Human Genome Sciences, Inc., Rockville, Maryland 20850; and {dagger} Charles River Laboratories Preclinical Services, Nevada, Sparks, Nevada 89431

Received December 19, 2005; accepted February 23, 2006

The tolerability, pharmacodynamic effects, and pharmacokinetics of belimumab (LymphoStat-B) were evaluated in cynomolgus monkeys. Belimumab is a fully human IgG1{lambda} antibody directed against B-lymphocyte stimulator (BLyS) protein. BLyS is a TNF family member that supports B-lymphocyte maturation and survival and has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies. Belimumab was developed to antagonize BLyS activity in autoimmune diseases and B-lymphocyte malignancies, where undesirable effects of B-lymphocyte activity may cause or contribute to disease. Pharmacodynamic effects of belimumab were monitored by immunophenotyping of peripheral blood. Pathology end points, including tissue immunophenotyping, are described after 13 and 26 weeks of treatment and after a 34-week treatment-free (recovery) period. Belimumab was safe and well tolerated in repeat-dose toxicology studies at 5–50 mg/kg for up to 26 weeks. Monkeys exposed to belimumab had significant decreases in peripheral blood B lymphocytes by 13 weeks of exposure, continuing into the recovery period, despite total lymphocyte counts similar to the controls. There were concomitant decreases in spleen and lymph node B-lymphocyte representation after 13 or 26 weeks of treatment with belimumab. Microscopically, monkeys treated with belimumab for 13 or 26 weeks had decreases in the number and size of lymphoid follicles in the white pulp of the spleen. All findings were generally reversible within a 34-week recovery period. These data confirm the specific pharmacologic activity of belimumab in reducing B lymphocytes in the cynomolgus monkey. The favorable safety profile and lack of treatment-related infections also support continued clinical development of belimumab.

Key Words: agents—pharmaceuticals; immunotoxicology—autoimmune; safety evaluation; safety evaluation—toxicity; chronic.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
R. Ponce
Preclinical Support for Combination Therapy in the Treatment of Autoimmunity with Atacicept
Toxicol Pathol, January 1, 2009; 37(1): 89 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
M Hegen, J C Keith Jr, M Collins, and C L Nickerson-Nutter
Utility of animal models for identification of potential therapeutics for rheumatoid arthritis
Ann Rheum Dis, November 1, 2008; 67(11): 1505 - 1515.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. L. Scholz, J. E. Crowley, M. M. Tomayko, N. Steinel, P. J. O'Neill, W. J. Quinn III, R. Goenka, J. P. Miller, Y. H. Cho, V. Long, et al.
BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact
PNAS, October 7, 2008; 105(40): 15517 - 15522.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. Carbonatto, P. Yu, M. Bertolino, E. Vigna, S. Steidler, L. Fava, C. Daghero, B. Roattino, M. Onidi, M. Ardizzone, et al.
Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept
Toxicol. Sci., September 1, 2008; 105(1): 200 - 210.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Y. Lin, Q. Gong, D. Seshasayee, Z. Lin, Q. Ou, S. Ye, E. Suto, J. Shu, W. Pun Lee, C.-W. V. Lee, et al.
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade
Blood, December 1, 2007; 110(12): 3959 - 3967.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.